Literature DB >> 8858164

Truncation of the COOH-terminal region of the paramyxovirus SV5 fusion protein leads to hemifusion but not complete fusion.

S Bagai1, R A Lamb.   

Abstract

The role of the simian virus 5 (SV5) fusion (F) protein 20 residue COOH-terminal region, thought to represent the cytoplasmic tail, in fusion activity was examined by constructing a series of COOH-terminal truncation mutants. When the altered F proteins were expressed in eukaryotic cells, by using the vaccinia virus-T7 transient expression system, all the F proteins exhibited similar intracellular transport properties and all were expressed abundantly on the cell surface. Quantitative and qualitative cell fusion assays indicated that all of the F protein COOH-terminal truncation mutants mediated lipid mixing with similar kinetics and efficiency as that of wild-type F protein. However, the cytoplasmic content mixing activity decreased in parallel with the extent of the deletion in the F protein COOH-terminal truncation mutants. These data indicate that it is possible to separate the presumptive early step in the fusion reaction, hemifusion, and the final stage of fusion, content mixing, and that the presence of the F protein COOH-terminal region is important for the final steps of fusion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8858164      PMCID: PMC2121019          DOI: 10.1083/jcb.135.1.73

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  70 in total

Review 1.  Intracellular aspects of the process of protein synthesis.

Authors:  G Palade
Journal:  Science       Date:  1975-08-01       Impact factor: 47.728

2.  Synthesis of influenza virus proteins in infected cells: translation of viral polypeptides, including three P polypeptides, from RNA produced by primary transcription.

Authors:  R A Lamb; P W Choppin
Journal:  Virology       Date:  1976-10-15       Impact factor: 3.616

3.  Asymmetric membranes resulting from the fusion of two black lipid bilayers.

Authors:  E Neher
Journal:  Biochim Biophys Acta       Date:  1974-12-24

4.  Mutations in the cytoplasmic domain of the fusion glycoprotein of Newcastle disease virus depress syncytia formation.

Authors:  T Sergel; T G Morrison
Journal:  Virology       Date:  1995-07-10       Impact factor: 3.616

5.  Evidence for a ninth influenza viral polypeptide.

Authors:  R A Lamb; P R Etkind; P W Choppin
Journal:  Virology       Date:  1978-11       Impact factor: 3.616

6.  Quantitative measurement of paramyxovirus fusion: differences in requirements of glycoproteins between simian virus 5 and human parainfluenza virus 3 or Newcastle disease virus.

Authors:  S Bagai; R A Lamb
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

8.  Individual roles of N-linked oligosaccharide chains in intracellular transport of the paramyxovirus SV5 fusion protein.

Authors:  S Bagai; R A Lamb
Journal:  Virology       Date:  1995-05-10       Impact factor: 3.616

9.  Membrane events involved in myoblast fusion.

Authors:  N Kalderon; N B Gilula
Journal:  J Cell Biol       Date:  1979-05       Impact factor: 10.539

10.  Membrane fusion during secretion. A hypothesis based on electron microscope observation of Phytophthora Palmivora zoospores during encystment.

Authors:  P Pinto da Silva; M L Nogueira
Journal:  J Cell Biol       Date:  1977-04       Impact factor: 10.539

View more
  38 in total

1.  A specific point mutant at position 1 of the influenza hemagglutinin fusion peptide displays a hemifusion phenotype.

Authors:  H Qiao; R T Armstrong; G B Melikyan; F S Cohen; J M White
Journal:  Mol Biol Cell       Date:  1999-08       Impact factor: 4.138

2.  Modification of the cytoplasmic domain of influenza virus hemagglutinin affects enlargement of the fusion pore.

Authors:  C Kozerski; E Ponimaskin; B Schroth-Diez; M F Schmidt; A Herrmann
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Amino acid sequence requirements of the transmembrane and cytoplasmic domains of influenza virus hemagglutinin for viable membrane fusion.

Authors:  G B Melikyan; S Lin; M G Roth; F S Cohen
Journal:  Mol Biol Cell       Date:  1999-06       Impact factor: 4.138

4.  The transmembrane domain sequence affects the structure and function of the Newcastle disease virus fusion protein.

Authors:  Kathryn A Gravel; Lori W McGinnes; Julie Reitter; Trudy G Morrison
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

5.  Mutations in multiple domains activate paramyxovirus F protein-induced fusion.

Authors:  Shaguna Seth; Andrew L Goodman; Richard W Compans
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

6.  C-terminal tyrosine residues modulate the fusion activity of the Hendra virus fusion protein.

Authors:  Andreea Popa; Cara Teresia Pager; Rebecca Ellis Dutch
Journal:  Biochemistry       Date:  2011-01-20       Impact factor: 3.162

7.  Role of the cytoplasmic tail of ecotropic moloney murine leukemia virus Env protein in fusion pore formation.

Authors:  G B Melikyan; R M Markosyan; S A Brener; Y Rozenberg; F S Cohen
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

8.  Polybasic KKR motif in the cytoplasmic tail of Nipah virus fusion protein modulates membrane fusion by inside-out signaling.

Authors:  Hector C Aguilar; Kenneth A Matreyek; Daniel Y Choi; Claire Marie Filone; Sophia Young; Benhur Lee
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

9.  Fusogenic variants of a noncytopathic paramyxovirus.

Authors:  Shaguna Seth; Ioanna Skountzou; Kim M Gernert; Richard W Compans
Journal:  J Virol       Date:  2007-02-07       Impact factor: 5.103

10.  Functional role of the cytoplasmic tail domain of the major envelope fusion protein of group II baculoviruses.

Authors:  Gang Long; Xiaoyu Pan; Marcel Westenberg; Just M Vlak
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.